Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
BACKGROUND
Non-enzymatic glycation of human serum albumin (HSA) is associated with the long-term complications of diabetes. We examined the structure and location of modifications on minimally-glycated HSA and considered their possible impact on the binding of drugs to this protein.


METHODS
Minimally-glycated and normal HSA (used as a control) were digested with trypsin, Glu-C or Lys-C, followed by fractionation of the resulting peptides and their analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to determine the structures and locations of glycation adducts.


RESULTS
Several specific lysine and arginine residues were identified as modification sites in minimally-glycated HSA. Residues K12, K51, K199, K205, K439 and K538 were found to be modified through the formation of fructosyl-lysine, while the modification of K159 and K286 involved the formation of pyrraline or N(epsilon)-carboxymethyl-lysine, respectively. Lysine K378 was found to give N(epsilon)-carboxyethyl-lysine in some forms of glycated HSA but fructosyl-lysine in other forms. Residues R160 and R472 produced a modification based on N(epsilon)-(5-hydro-4-imidazolon-2-yl)ornithine. Lysine R222 was modified to produce argpyrimidine, N(epsilon)-[5-(2,3,4-trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine or tetrahydropyrimidine.


CONCLUSIONS
With the exception of K12, K199, K378, K439 and K525, all of the observed sites of modification for minimally-glycated HSA were new to this current study. The fact that many of these glycation-related modifications are located at or near known drug binding sites on HSA explains why some differences have been previously noted in the binding of certain drugs to normal vs glycated HSA.
Wa
Chunling
C
Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304, United States.
Cerny
Ronald L
RL
Clarke
William A
WA
Hage
David S
DS
D000595:Amino Acid Sequence; D050260:Carbohydrate Metabolism; D002241:Carbohydrates / Q000032:analysis* / Q000097:blood / Q000737:chemistry*; D018698:Glutamic Acid / Q000737:chemistry / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000032:analysis* / Q000097:blood; D006801:Humans; D008239:Lysine / Q000737:chemistry / Q000378:metabolism; D008958:Models, Molecular; D008969:Molecular Sequence Data; D015394:Molecular Structure; D017434:Protein Structure, Tertiary; D012709:Serum Albumin / Q000737:chemistry* / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*; D014357:Trypsin / Q000378:metabolism
D002241:Carbohydrates; D017127:Glycation End Products, Advanced; D012709:Serum Albumin; D018698:Glutamic Acid; D014357:Trypsin; D008239:Lysine
Biochem Pharmacol. 1992 Apr 15;43(8):1829-34
1575775
Arch Biochem Biophys. 2003 Nov 1;419(1):1-15
14568003
Diabetologia. 1996 Feb;39(2):149-60
8635666
Rapid Commun Mass Spectrom. 1996;10(11):1371-8
8805846
Electrophoresis. 1997 Mar-Apr;18(3-4):403-8
9150918
Anal Chem. 1997 Jul 1;69(13):2457-63
9212708
Life Sci. 1998;62(23):2141-50
9627093
J Biol Chem. 2005 Feb 18;280(7):5724-32
15557329
J Biol Chem. 2005 Jun 17;280(24):22582-9
15837789
Ann N Y Acad Sci. 2005 Jun;1043:249-59
16037245
Ann N Y Acad Sci. 2005 Jun;1043:267-75
16037247
Proteins. 2005 Dec 1;61(4):704-21
16231289
Anal Biochem. 2006 Feb 15;349(2):229-41
16356458
Kidney Int. 2000 Nov;58(5):2228-34
11044246
Mass Spectrom Rev. 2000 Sep-Oct;19(5):279-304
11079246
Recent Prog Horm Res. 2001;56:1-21
11237208
Electrophoresis. 2001 Aug;22(14):2844-55
11565779
Trends Biochem Sci. 2002 Feb;27(2):107-9
11852249
Biochem J. 2002 May 15;364(Pt 1):1-14
11988070
Biochem J. 2002 May 15;364(Pt 1):15-24
11988071
J Mass Spectrom. 2003 Feb;38(2):196-205
12577286
Nucleic Acids Res. 2003 Jul 1;31(13):3316-9
12824316
J Am Soc Mass Spectrom. 2003 Sep;14(9):992-1002
12954167
J Biomol Tech. 2003 Sep;14(3):224-30
13678153
Clin Pharmacokinet. 1991 Jun;20(6):477-90
2044331
Science. 1990 Jul 20;249(4966):302-3
2374930
Pharm Res. 1988 May;5(5):261-5
3149736
Ther Drug Monit. 1987 Dec;9(4):389-91
3122377
J Biol Chem. 1986 Oct 15;261(29):13542-5
3759977
J Biol Chem. 1984 Mar 25;259(6):3812-7
6706980
J Biol Chem. 1983 May 25;258(10):6142-6
6853480
J Pharm Sci. 1982 Feb;71(2):235-8
7062252
J Biol Chem. 1979 Feb 10;254(3):595-7
762083
J Am Soc Mass Spectrom. 2004 Apr;15(4):496-509
15047055
Biochem J. 2003 Nov 1;375(Pt 3):581-92
12885296
Biol Pharm Bull. 1994 Nov;17(11):1505-7
7703973